← Back to Clinical Trials
Recruiting NCT06606353

NCT06606353 Talk-to-Jo" Intelligent Digital Health Companion, Neurocognitive Disorders and Dyads

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06606353
Status Recruiting
Phase
Sponsor Olivier Beauchet
Condition Caregiver
Study Type OBSERVATIONAL
Enrollment 40 participants
Start Date 2024-12-12
Primary Completion 2026-02

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Talk-To-Jo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 40 participants in total. It began in 2024-12-12 with a primary completion date of 2026-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

By 2050, one in six people in the world will be over 65, leading to an increase in the number of people with neurocognitive disorders (NCD), such as Alzheimer's disease. The number of cases will rise from 57 million to 153 million by 2050. This presents challenges for healthcare systems, as NCDs affect not only mental health but also the physical health, psychological well-being, and social relationships of patients, as well as their caregivers (PCA). In Quebec, primary care is often inadequate for people living with NCDs due to delays in accessing resources, incomplete coverage of needs, and the COVID-19 pandemic, which has exacerbated these challenges. This situation can lead to a deterioration in patients' health, affecting their quality of life as well as that of their PCAs, while also increasing healthcare costs. Many elderly people wish to age at home, but cognitive and functional decline complicates this desire. PCAs, generally family members or close friends, play an essential role in the daily support of these individuals. Their role, as defined in the Act to support caregivers in Quebec, includes non-professional and voluntary assistance to improve the quality of life of the person being cared for. However, the support provided by PCAs can lead to significant stress, especially if public services are insufficient. The exhaustion of PCAs is often correlated with the severity of the care recipient's loss of autonomy. This exhaustion impacts the mental and physical health of PCAs, leading to isolation, depression, and anxiety, as well as reduced productivity and an increase in sick leave. It is therefore urgent to find support solutions to prevent PCA burnout. Telehealth, which involves remote consultations through information and communication technologies (ICT), appears to be a promising solution to improve access to care for people with NCDs, especially in underserved areas. By enabling remote monitoring, telehealth facilitates aging in place while stimulating the remaining capacities of patients, such as responsiveness to sensory stimuli. Artificial intelligence (AI) is also a promising tool for tracking the health of older adults in real-time, detecting early signs of diseases, and providing personalized recommendations. Virtual assistants or avatars, like "Talk-to-Jo," can interact with patients to reduce their sense of loneliness. However, the effectiveness of these technologies depends on their accessibility and adaptability to the needs of patients, particularly in cases of sensory impairments. "Talk-to-Jo" is a digital avatar designed for older adults with NCDs and their PCAs. It asks questions about memory and depression and provides tailored recommendations to prevent or stabilize detected disorders. A first version of this tool is currently available on a tablet. With the growing number of people living with NCDs, it is essential to develop support solutions based on telemedicine and AI. It is important to assess the usability and acceptability of these technologies by patients and their PCAs to ensure their effectiveness.

Eligibility Criteria

1. Person living with an neurocognitive disorder (NCD): 1. Inclusion criteria: * Be 65 years old or older. * Have an NCD, whether minor or major, in a mild to moderate stage, diagnosed within the past year. * Be receiving care for an NCD at the outpatient clinic of the Montreal Geriatric University Institute. * Have a caregiver. * Live in a personal residence or in a non-medicalized senior residence. * Be able to understand spoken and written French. The "Talk-to-Jo" avatar has only been developed in the French language and can only communicate and understand French. 2. Exclusion criteria: * Inability to provide informed consent for participation in the study. * Participating in a concurrent experimental clinical study, to avoid interference with our study. * Living in a Long-Term Care Facility or in a medicalized section of an non-medicalized senior residence. * Inability to understand spoken and written French. * Having a moderate to severe visual or auditory impairment. The criterion for assessing hearing impairment will be the person's ability to understand and participate in a phone conversation. Individuals with impairments who use hearing aids or glasses to compensate for the impairments may be included. 2. Caregiver 1. Inclusion criteria: * Be a caregiver for a person living with an NCD (regardless of the relationship: spouse, child, friend, neighbor, family member). * Be able to understand spoken and written French. 2. Exclusion criteria: * Have an NCD. * Inability to understand spoken and written French. * Participating in a concurrent experimental clinical study, to avoid interference with our study. * Having a moderate to severe visual or auditory impairment. The criterion for assessing hearing impairment will be the person's ability to understand and participate in a phone conversation. Individuals with impairments who use hearing aids or glasses to compensate for the impairments may be included.

Contact & Investigator

Central Contact

Olivier Beauchet, MD

✉ olivier.beauchet@umontreal.ca

📞 5143403540

Frequently Asked Questions

Who can join the NCT06606353 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Caregiver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06606353 currently recruiting?

Yes, NCT06606353 is actively recruiting participants. Contact the research team at olivier.beauchet@umontreal.ca for enrollment information.

Where is the NCT06606353 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT06606353 clinical trial?

NCT06606353 is sponsored by Olivier Beauchet. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology